Evidence map›Paper›PMID 32483359›Full record

Trial reportNature medicine2020

Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis.

Priscilla K Brastianos, Eudocia Quant Lee, Justine V Cohen, Sara M Tolaney, Nancy U Lin, Nancy Wang, Ugonma Chukwueke, Michael D White, Naema Nayyar, Albert Kim and 22 more

Erratum issuedAbstract readClinical Trial, Phase II
PubMed Publisher
In one paragraph

Trial report in Nature medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 101 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
101citing papers in PubMed, 5 pooled it
12.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

101 citing papers in PubMed, 5 syntheses or guidelines pooled it, 153 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. The evolving landscape of leptomeningeal metastases from NSCLC: an international, contemporary, multicenter cohort study.Annals of oncology : official journal of the European Society for Medical Oncology · 2026
    Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

41 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

32 authors at 1 institution in 1 country.

Priscilla K BrastianosMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA. pbrastianos@mgh.harvard.edu.ORCID http://orcid.org/0000-0003-4470-8425
Eudocia Quant LeeDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Justine V CohenMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Sara M TolaneyDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Nancy U LinDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Nancy WangMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Ugonma ChukwuekeDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Michael D WhiteMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-3855-9243
Naema NayyarMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Albert KimMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Christopher Alvarez-BreckenridgeMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Ian KropDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Maura Keeley MaharMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Mia S BertalanMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Brian ShawMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Joana L MoraMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Nathaniel GossMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Megha SubramanianMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Lakshmi NayakDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Jorg DietrichMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Deborah A ForstMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Brian V NahedMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Tracy T BatchelorMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Helen A ShihMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Elizabeth R GerstnerMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Beverly MoyMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Donald LawrenceMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Anita Giobbie-HurderDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Scott L CarterDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-8480-1475
Kevin OhMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Daniel P Cahill *Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Ryan J Sullivan *Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-5344-6645
Harvard University · US

Funding

Identification of genomic drivers of brain metastases in lung adenocarcinomaR01CA227156 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI BRASTIANOS, PRISCILLA KALIOPI, CARTER, SCOTT · 2018 to 2022
$3.5M
Using MRI and circulating tumor DNA to improve the interpretation of response to immunotherapy and targeted therapy in CNS metastasesR01CA244975 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI BRASTIANOS, PRISCILLA KALIOPI, GERSTNER, ELIZABETH · 2020 to 2024
$3.4M
Identification of genomic drivers of brain metastases in renal cell carcinomaR21CA220253 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI BRASTIANOS, PRISCILLA KALIOPI, CARTER, SCOTT · 2018 to 2019
$421k
U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) 1R01CA227156-01U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) 1R01CA244975-01U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) 5R21CA220253-02
6 · The paper itself

Abstract

An increasing fraction of patients with metastatic cancer develop leptomeningeal dissemination of disease (LMD), and survival is dismal

Indexed as

Antibodies, Monoclonal, HumanizedBreast NeoplasmsDisease-Free SurvivalDose-Response Relationship, DrugFemaleHumansHyperglycemiaLung NeoplasmsMeningeal CarcinomatosisNauseaNeoplasm MetastasisOvarian NeoplasmsVomitingAntibodies, Monoclonal, Humanizedpembrolizumab

Identifiers

PMID32483359
OpenAlexW3031665354

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.